Paper of the Month

Our authors of the month conducted this study in which COVID-19 patients with neurological symptoms and cognitive impairments, underwent DMI in the subacute stage of the disease.

In this population-based study, the authors aimed to investigate whether increased life expectancy determined by the adherence to a healthy lifestyle has an impact on the overall years lived with AD across the lifespan.

To evaluate the association of COVID-19 infection with olfactory bulb, our authors of the month conducted this multicenter postmortem cohort study, using ultrastructural and histopathological analysis.

Our authors of the month evaluated an experimental treatment for human prion disease, based on a fully humanised monoclonal antibody (PRN100) addressed against the cellular prion protein (PrP).

Our authors of the month conducted this retrospective case-control study in order to investigate the association of AD with the risk of COVID-19 infection (adjusted for comorbidities and sociodemographic factors).

Our paper of the month describes a study led by Stanford University researchers, which now provides a mechanistic basis for how EBV infection can trigger the patient’s immune cells to attack self-tissue within the CNS.

Our authors of the month conducted a longitudinal, multi-modal brain imaging study using the UK biobank, whereby participants had already been scanned before getting infected with SARS-CoV-2, offering a unique resource to elucidate these questions.

Our authors of the month conducted a systematic retrospective analysis of 150 lumbar punctures in 127 patients with PCR-proven COVID-19 and neurological symptoms seen at 17 European university centres.

Our research paper of the month for March is a cohort study exploring the risk of developing multiple sclerosis (MS) after infection with Epstein-Barr virus (EBV).

Our authors of the month conducted a systematic review and meta-analysis in order to summarise the frequency of neurologic manifestations in patients with COVID-19 and to investigate the association of these manifestations with disease severity and mortality.

For February we have selected Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomized, placebo-controlled trial.

Our research paper of the month is a multicentre, randomised and double-blind phase 2 study with a futility design, exploring the efficacy and the safety of guanabenz in patients with probable or definite amyotrophic lateral sclerosis (ALS).

Our authors of the month conducted a systematic review of SARS-CoV-2-associated deaths in Hamburg, Germany, from March to December 2020, using conventional autopsy, ultrasound-guided minimally invasive autopsy, postmortem computed tomography (PMCT) and medical record review.

Our research paper of the month is an open-label, single-arm, phase II futility trial exploring the safety and the effect of treatment with the antimalarial drug hydroxychloroquine on disability worsening in patients with primary progressive multiple sclerosis.

Our authors of the month conducted a randomised, placebo-controlled, observer-blinded, multinational study to assess the safety, efficacy and immunogenicity of the BNT162b2 vaccine.